By studying and exploring the role and mechanism of the CXCR2 inhibitor Nav in MI-induced heart failure, we provide an experimental basis for CXCR2 inhibitors becoming a new therapeutic target for MI in the future. This evidence concerns the gene CXCR2 and myocardial infarction.